Get the Stockscreener App
24.64
0.08%
-0.02
Galapagos Nv Adr stock is traded at $24.64, with a volume of 152.20K.
It is down -0.08% in the last 24 hours and down -4.57% over the past month.
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
See More
Previous Close:
$24.66
Open:
$24.52
24h Volume:
152.20K
Relative Volume:
0.53
Market Cap:
$1.62B
Revenue:
$282.04M
Net Income/Loss:
$221.88M
P/E Ratio:
7.3207
EPS:
3.3658
Net Cash Flow:
$-449.57M
1W Performance:
+1.82%
1M Performance:
-4.57%
6M Performance:
-20.64%
1Y Performance:
-15.27%
1-Day Range:
$24.31
$24.79
1-Week Range:
$23.36
$24.91
52-Week Range:
$22.36
$31.23
Galapagos Nv Adr Stock (GLPG) Company Profile
Compare GLPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
24.64 | 1.62B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-24 | Downgrade | Kepler | Hold → Reduce |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-02-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-28-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-24-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-23 | Upgrade | Jefferies | Underperform → Hold |
| Nov-07-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-27-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-19-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Apr-14-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-23-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Feb-19-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-19-20 | Initiated | Maxim Group | Buy |
| Oct-21-20 | Downgrade | Goldman | Neutral → Sell |
| Aug-25-20 | Downgrade | Jefferies | Buy → Hold |
| Aug-24-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-19-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| Jul-10-20 | Downgrade | Stifel | Buy → Hold |
| Mar-30-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-25-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Jan-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-02-19 | Initiated | BofA/Merrill | Neutral |
| Sep-09-19 | Resumed | Morgan Stanley | Overweight |
| Jul-31-19 | Upgrade | UBS | Neutral → Buy |
| Jul-29-19 | Downgrade | Jefferies | Buy → Hold |
View All
Galapagos Nv Adr Stock (GLPG) Latest News
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 - GlobeNewswire Inc.
Galapagos To Spin Off Innovative Medicines Business - Forbes
Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos NV announces retirement of CEO - Seeking Alpha
Galapagos Gets First Commercial Drug With Jyseleca Approval - Yahoo Finance
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts - Yahoo Finance
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com
AIM tech shares that broke America - Interactive Investor
Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
Galapagos Nv Adr Stock (GLPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):